Quick Answer
Cartesian Therapeutics, Inc. reported Total Revenue of $2.80 million for the year ending 2025.
- Cartesian Therapeutics, Inc. showed an increase of +599.3% in Total Revenue from 2025 to 2025.
- This data is from Cartesian Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2014 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2015: $1.03 million | Q2 2015: $1.24 million | Q3 2015: $1.61 million | Q4 2015: $2.13 million | Q1 2016: $2.09 million | Q2 2016: $2.02 million | Q3 2016: $1.05 million | Q4 2016: $2.93 million | Q1 2017: $137.0 thousand | Q1 2017: $137.0 thousand | Q2 2017: $26.0 thousand | Q2 2017: $26.0 thousand | Q3 2017: $27.0 thousand | Q3 2017: $27.0 thousand | Q4 2017: $17.0 thousand | Q4 2017: $17.0 thousand | Q1 2018: $0.00 | Q1 2018: $0.00 | Q2 2018: $0.00 | Q3 2018: $0.00 | Q4 2018: $903.0 thousand | Q1 2019: $10.0 thousand | Q2 2019: $13.0 thousand | Q3 2019: $0.00 | Q4 2019: $6.65 million | Q1 2020: $0.00 | Q2 2020: $0.00 | Q3 2020: $4.65 million | Q1 2021: $11.05 million | Q2 2021: $19.66 million | Q3 2021: $24.43 million | Q1 2022: $34.00 million | Q2 2022: $39.27 million | Q3 2022: $20.71 million | Q1 2023: $5.94 million | Q2 2023: $5.25 million | Q2 2023: $5.25 million | Q3 2023: $6.55 million | Q3 2023: $6.55 million | Q1 2024: $5.84 million | Q1 2024: $5.84 million | Q2 2024: $33.27 million | Q2 2024: $33.45 million | Q3 2024: $0.00 | Q3 2024: $387.0 thousand | Q1 2025: $1.10 million | Q1 2025: $400.0 thousand | Q2 2025: $0.00 | Q2 2025: $298.0 thousand | Q3 2025: $0.00 | Q3 2025: $452.0 thousand.
- Over the full 17 years of available data (2014 to 2025), Cartesian Therapeutics, Inc.'s Total Revenue has declined by 8.0%.
- Historical annual values: Fiscal year 2025: $2.80 million | Fiscal year 2025: $400.0 thousand | Fiscal year 2024: $38.91 million | Fiscal year 2024: $38.28 million | Fiscal year 2023: $26.00 million | Fiscal year 2023: $26.00 million | Fiscal year 2022: $110.78 million | Fiscal year 2021: $85.08 million | Fiscal year 2020: $16.60 million | Fiscal year 2019: $6.68 million | Fiscal year 2018: $903.0 thousand | Fiscal year 2017: $207.0 thousand | Fiscal year 2017: $207.0 thousand | Fiscal year 2016: $8.08 million | Fiscal year 2016: $8.08 million | Fiscal year 2015: $6.01 million | Fiscal year 2014: $3.04 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: